TGTX: TG Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3,056.93
Enterprise Value ($M) 3,076.94
Book Value ($M) 160.11
Book Value / Share 1.12
Price / Book 19.09
NCAV ($M) 165.51
NCAV / Share 1.15
Price / NCAV 18.47

Profitability (mra)
Return on Invested Capital (ROIC) 0.35
Return on Assets (ROA) 0.29
Return on Equity (ROE) 2.37

Liquidity (mrq)
Quick Ratio 2.83
Current Ratio 3.58

Balance Sheet (mrq) ($M)
Current Assets 389.15
Assets 401.21
Liabilities 223.64
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
2 days ago 13G/A BlackRock, Inc. 14.20
02-14 13G/A Darwin Global Management, Ltd. 2.70 -61.28
02-13 13G/A Vanguard Group Inc 9.03 -11.82
01-26 13G/A BlackRock Inc. 7.10 17.91
01-25 13G/A State Street Corp 5.45 -20.75

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-09 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. ☐ TRANSITION REP
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. ☐ TRANSITION REPORT PURSUANT TO SECT
2023-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-10-08 476,518 1,987,278 23.98
2024-10-07 628,661 1,861,783 33.77
2024-10-04 533,997 2,038,882 26.19
2024-10-03 302,176 1,032,900 29.26

(click for more detail)

Similar Companies
TELO – Telomir Pharmaceuticals, Inc. TENX – Tenax Therapeutics, Inc.
TFFP – TFF Pharmaceuticals, Inc. THAR – Tharimmune, Inc.
THTX – Theratechnologies Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: TG Therapeutics